Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...

Wedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. Market sentiment ...

Tesla’s Elon Musk and his close relationship with President-elect Trump are already having a huge impact on the EV maker, ...

News of an investigation by the Federal Trade Commission into Microsoft (NASDAQ:MSFT) is "not a worry" with Chairwoman Lina ...

Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...

We recently published a list of 15 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a ...

The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...

Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s ...

Gary Black of The Future Fund LLC confirmed that Tesla's Cybercab won't launch until 2026, dismissing early rollout rumors, ...

Ken Griffin of Citadel sold 5.1 million shares of Palantir, reducing his stake by 91%. Meanwhile, he bought 4.7 million ...

Tesla (NASDAQ:TSLA) could reach a $2 trillion valuation over the next 12 to 18 months as full-self-driving, autonomous ...

Wedbush has an outperform rating on Apple's stock heading into the holiday season and a 12-month price target of $300, that's about 28% above its current price. It's the highest price target among the ...